ATTD Newsletter July

Diabetes Technology Connection
  July 22, 2014   Share with a Colleague





Apple iWatch

The new iWatch? Only time will tell.


Apple, Samsung, Google compete to apply mobile technology to diabetes

Tech giants Apple, Samsung, and Google are aiming to make an impact on the wearable technology market through the development of new wearable devices that will be used to monitor blood sugar. Sources say the companies are asking U.S. regulators about oversight and developing noninvasive glucose-measuring features in future devices. Google has developed a “smart” contact lens that measures glucose levels in tears using an LED system and is seeking partners to bring the lens to market. Apple’s iWatch will purportedly be available in October. It is not confirmed that the iWatch will incorporate glucose-tracking sensors, but Apple has brought in experts in glucose sensing. Samsung, say sources, is working with startups to implement a system in future Galaxy Gear smartwatches that flashes blood-sugar warnings.

Read More
ATTD 2015: Paris, France

Updates from the Field

European Medicines Agency requires sponsors to post trial results
As of July 21, 2014, sponsors will be required to post clinical trial results in the European Clinical Trials Database (EudraCT), managed by the European Medicines Agency (EMA). Consequently, summary results of clinical trials will be made publicly accessible via the European Union Clinical Trials Register. Sponsors will have to upload results to EudraCT within six or twelve months following the end of the trial; for trials ending prior to July 21, 2014, results must be submitted retrospectively. Going forward, the European Union Clinical Trials Register will provide public access to summary results for clinical trials conducted in European Economic Area (EEA) countries, as well as for trials linked to European pediatric drug development that are conducted in third countries.

For More Information

Cost of diabetes reaches $245 billion in U.S.
The U.S. Centers for Disease Control and Prevention released statistics about diabetes and its burden on the country in the National Diabetes Statistics Report, 2014. The report found 29.1 million people, or 9.3% of the population, had diabetes in 2012, with 21 million diagnosed and the remaining 8.1 million unaware they have the disease. About 1.7 million new cases are diagnosed annually. Approximately 208,000 young people, less than 20 years old, have been diagnosed with type 1 or type 2 diabetes, representing 0.25% of all people in this age group. Total direct and indirect costs of diabetes are $245 billion: $176 billion in direct costs and $69 billion in lost time from work, disability, and premature death.

For More Information

Outcomes of pediatric patients in the German/Austrian DPV and U.S. T1D Exchange registries
A recent study by Maahs et al. (Diabetologia, June 2014) compared participant characteristics, treatment modalities, and clinical outcomes in children, under the age of 6, with type 1 diabetes. Subjects included 2,622 participants in the Prospective Diabetes Follow-up Registry (DPV) or the T1D Exchange. Insulin pump use was more frequent (74% vs 50%) in the DPV than in the T1D Exchange. A lower HbA1c level was seen in the DPV (mean 7.4%) compared with the T1D Exchange (mean 8.2%). The frequency of severe hypoglycemia did not differ between registries or by HbA1c, whereas the frequency of diabetic ketoacidosis was higher for the T1D Exchange and greater in those with higher HbA1c levels.

For More Information


Take the lead and
submit your research to ATTD

The Advanced Technologies & Treatments for Diabetes Conference is now accepting oral and poster discussion abstracts for its February 18-21, 2015 event in Paris, France. All abstracts will be peer reviewed prior to acceptance for presentation at the event. All accepted abstracts will be published in the journal Diabetes Technology & Therapeutics. Abstracts must be submitted in English through an online submission form.

For More Information


Sanofi and Medtronic partner on diabetes drug-device combos
France-based pharmaceutical company Sanofi and U.S. medical device firm Medtronic have formed a global strategic alliance to develop drug-device combinations and care management services for people with type 2 diabetes. They aim to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition. The partnership combines Sanofi’s insulin portfolio and drug development capabilities with Medtronic’s expertise in insulin pumps and continuous glucose monitoring.

For More Information

The latest ATTD yearbook, Advanced Technologies & Treatments for Diabetes
Complimentary access to ATTD Yearbook

The latest ATTD yearbook, Advanced Technologies & Treatments for Diabetes, a concise update on key topics with a review of the published literature, is available online with free access. The top-read chapters are: Continuous Glucose Monitoring by Tadej Battelino and Bruce Bode; and Self-monitoring of Blood Glucose by Satish Garg and Irl Hirsch. Other chapters cover physical activity and exercise, new insulins and insulin therapy, and new therapies for diabetes management, insulin pumps, pens, and other delivery devices, artificial pancreas, bariatric surgery, health information technology, and more.

For More Information
Expert Spotlight
MD, Moshe Phillip, MD

Moshe Phillip, MD
Dr. Phillip is vice dean and head of the School for Continuing Medical Education at the Sackler Faculty of Medicine at Tel Aviv University in Israel. His research focuses on better metabolic control and the immunomodulation and prevention of diabetes mellitus. He has pioneered research in developing an artificial pancreas. He is co-chairman of the 8th International Conference on Advanced Technologies & Treatments for Diabetes.

Stephanie Amiel, MD, head of Diabetes & Nutritional Sciences at King’s College London, is one of several principal investigators on the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT).

V. Mohan, MDV. Mohan, MD, chairman of the V. Mohan Diabetes Specialties Center in Chennai, India, and director and chief of Diabetes Research at the Madras (India) Diabetes Research Foundation, addressed controversies in Postprandial Glycemic Excursions and Cardiovascular Risk at the ATDC Keystone Conference on July 17.

Juleen Zierath, PhDJuleen Zierath, PhD, an expert in metabolism and diabetes at the Karolinska Institutet in Stockholm, is the first female Chair of the Nobel Committee for Physiology or Medicine.

Edward Horton, MD, senior investigator at Joslin Diabetes Center and professor of Medicine at Harvard Medical School, won the American Diabetes Association’s 2014 Albert Renold Award given annually to an individual who has made a significant impact as a mentor to diabetes researchers or to a community of diabetes investigators.

Stephen Colagiuri, MD, professor of Metabolic Health and co-director of the Boden Institute at the University of Sydney, has been named chair of the International Diabetes Federation Clinical Guidelines Taskforce.

Stavroula Mougiakakou, PhD, from the ARTORG Center for Biomedical Engineering Research of the University of Bern, and Peter Diem, MD, from the University’s Department of Endocrinology, Diabetes and Clinical Nutrition, direct GoCARB, a four-year international research project developed in close cooperation with Roche Diagnostics and financed by the European Commission in the 7th research framework programme.

Catherine (Katie) M. SzymanCatherine (Katie) M. Szyman, a long-time Medtronic executive, has become senior vice president and leader of Medtronic’s global channel management strategy; and Hooman Hakami is now executive vice president and group president of Medtronic’s diabetes business. He most recently served as president and CEO of GE Healthcare’s detection and guidance unit.

Expert on the Move

Significant gender differences in diabetics’ CV risk factors
Cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women with type 2 diabetes, according to a new study in Diabetes Technology & Therapeutics. Joni Strom Williams, MD, MPH, and colleagues from the Medical University of South Carolina and Ralph H. Johnson VA Medical Center in Charleston, S.C., conducted a cross-sectional study involving 680 people with type 2 diabetes from three primary care settings. They found unadjusted mean systolic blood pressure and LDL cholesterol levels were significantly higher in women than men. The authors concluded that it was “imperative that women are informed about CVD risk factors, educated on how to reduce them, and aggressively treated to avoid adverse outcomes.”

For More Information

Large study shows hospital admissions for hypoglycemia on the rise among older adults
Since 1999, higher hypoglycemia hospitalization rates have been observed among adults age 65 years or older in the U.S., reports a study by Lipska et al. (JAMA Intern Med., July 1, 2014). Using data from nearly 34 million Medicare patients, researchers found that, between 1999 and 2011, rates of admissions for hyperglycemia declined by 38.6% while admissions for hypoglycemia increased by 11.7%. Hypoglycemia rates were 2-fold higher for patients 75 years and older, and admission rates for both hyperglycemia and hypoglycemia were 4-fold higher for black patients compared with white patients. For both hyper- and hypoglycemia, the 30-day and 1-year mortality and 30-day readmission rates improved during the study period.

For More Information

European Foundation unveils travel fellowships for young scientists
The European Foundation for the Study of Diabetes announced that the Albert Renold Travel Fellowships for Young Scientists, supported by Merck Sharp & Dohme, is accepting applications. The program provides funding for young scientists to travel and stay at other European institutions for up to three months, providing an opportunity to learn different scientific techniques related to diabetes research. Those who receive the award must provide a written report and confirmation of their work at the host institution. Fellowships are awarded for up to 8,000 euros.

For More Information

Fully automated artificial pancreas nearing reality
A recent article in JAMA outlines progress being made in the six-step process toward an artificial pancreas that can dispense insulin and other pancreatic hormones based on real-time changes in blood sugar levels. The first step, a product that continuously monitors glucose levels and stops delivering insulin when the level drops too low, already exists and is being marketed by Medtronic. The company plans to introduce a step 2 device, which will predict low levels and stop or reduce the amount of insulin provided to avoid reaching a low. Looking toward the future, step 3 products would include a hypoglycemia/hyperglycemia minimizer, designed to prevent high and low blood sugar levels; step 4, a hybrid closed-loop product, would target a specific blood sugar level, rather than a range; step 5 products would eliminate manually administering insulin before meals; and step 6 devices could dispense additional hormonal drugs, such as glucagon.

For More Information

Groundbreaking research focuses on stem cell-based treatment of diabetes
The HumEn project, led by Professor Henrik Semb from the Danish Stem Cell Center (DanStem) at the University of Copenhagen, received a 6 million euros, four-year grant through the European Commission’s HEALTH research programme. The project will bring together leading European stem cell research groups and industrial partners to develop glucose-responsive, insulin-producing beta cells for future cell-replacement therapy in diabetes. The project is expected to keep Europe on the forefront of stem cell research, creating new commercial possibilities and greater competitiveness for the European biomedical industry.

For More Information


  ATTD 2015: Paris, France

Advanced Technologies & Treatments for Diabetes has gathered top experts in the field as Program Advisors for the 2015 conference in Paris, including: Stephanie Amiel, UK; J Hans DeVries, the Netherlands; Satish Garg, USA; Lutz Heinemann, Germany; Irl Hirsch, USA; Roman Hovorka, UK; Neal Kaufman, USA; Eric Renard, France; and Jay Skyler, USA.


Satish K Garg, MD  

ATTD names Diabetes Technology & Therapeutics its official journal. Satish K Garg, MD, professor of Medicine and Pediatrics at the University of Colorado Denver, serves as Editor-in-Chief of the Journal. Conference attendees receive a special online subscription rate to the only peer-reviewed journal providing information about new devices, drugs, medication delivery systems, and software for diabetes management.

For More Information